Xlife Sciences AG - ESG Rating & Company Profile powered by AI
Complete ESG analysis of Xlife Sciences AG can be accessed by signing in. Alternative corporations in the rating peer group for Xlife Sciences AG are displayed below. This assessment of Xlife Sciences AG is prepared by All Street Sevva using cutting edge NLP.
Xlife Sciences AG in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Xlife Sciences AG | 8.0 | High |
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Xlife Sciences AG have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Xlife Sciences AG disclose current and historical energy intensity?
Sign up for free to unlockDoes Xlife Sciences AG report the average age of the workforce?
Sign up for free to unlockDoes Xlife Sciences AG reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Xlife Sciences AG disclose its ethnicity pay gap?
Sign up for free to unlockDoes Xlife Sciences AG disclose cybersecurity risks?
Sign up for free to unlockDoes Xlife Sciences AG offer flexible work?
Sign up for free to unlockDoes Xlife Sciences AG have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Xlife Sciences AG disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Xlife Sciences AG conduct supply chain audits?
Sign up for free to unlockDoes Xlife Sciences AG disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Xlife Sciences AG conduct 360 degree staff reviews?
Sign up for free to unlockDoes Xlife Sciences AG disclose the individual responsible for D&I?
Sign up for free to unlockDoes Xlife Sciences AG disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Xlife Sciences AG disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Xlife Sciences AG disclose water use targets?
Sign up for free to unlockDoes Xlife Sciences AG have careers partnerships with academic institutions?
Sign up for free to unlockDid Xlife Sciences AG have a product recall in the last two years?
Sign up for free to unlockDoes Xlife Sciences AG disclose incidents of discrimination?
Sign up for free to unlockDoes Xlife Sciences AG allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Xlife Sciences AG issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Xlife Sciences AG disclose parental leave metrics?
Sign up for free to unlockDoes Xlife Sciences AG disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Xlife Sciences AG disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Xlife Sciences AG disclose the pay ratio of women to men?
Sign up for free to unlockDoes Xlife Sciences AG support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Xlife Sciences AG disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Xlife Sciences AG reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Xlife Sciences AG involved in embryonic stem cell research?
Sign up for free to unlockDoes Xlife Sciences AG disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Xlife Sciences AG disclose its waste policy?
Sign up for free to unlockDoes Xlife Sciences AG report according to TCFD requirements?
Sign up for free to unlockDoes Xlife Sciences AG disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Xlife Sciences AG disclose energy use targets?
Sign up for free to unlockDoes Xlife Sciences AG disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Xlife Sciences AG have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Xlife Sciences AG
These potential risks are based on the size, segment and geographies of the company.
Xlife Sciences AG focuses on the development and commercialization of technologies in the life sciences industry. The company's project consists of technology platforms that focuses to identify new therapeutic approaches and biomarkers for common diseases based on human genetic data; focuses on functional screening of antibodies by microfluidics-based technologies; and provides services for drug development. It also develops mono-and bispecific anti-tumor antibodies for the treatment of life-threatening diseases, with a focus on orphan hematopoietic malignancies; researches, develops, and manufactures chemical and active pharmaceutical ingredients for human and veterinary medicine; and develops new methods for the early identification of kidney diseases. In addition, the company develops and implements projects for cellular 3D screen printing of biomaterials for medical and biotechnological sector; new drug delivery system for the controlled release of pharmaceutical actives; and Neuromex, a screening instrument for the early-stage detection of neurodegenerative diseases, as well as supplies circular systems for complex medical devices. Further, it develops artificial intelligence-based computer-assisted diagnostic systems for medical professionals. The company is based in Zurich, Switzerland.